Genetics and molecular markers in gestational trophoblastic disease with reference to their clinical application

Bailliere's Best Practice and Research in Clinical Obstetrics and Gynaecology

Volumn 17, Issue 6, 2003, Pages 827-836

  Matsuda, Takao ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Androgenesis; Choriocarcinoma; Complete mole; Imprinting; Monoallelic contribution; Tumour suppressor genes

Indexed keywords

ANTINEOPLASTIC AGENT; BIOCHEMICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HERMES ANTIGEN; INTERLEUKIN 1; JANUS KINASE; MYC PROTEIN; PLACENTA LACTOGEN; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; PROTEIN P57; RAD52 PROTEIN; RAS PROTEIN; RETINOBLASTOMA PROTEIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; STAT5B PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; VERSICAN;

ALLELE; ANDROGENESIS; CARCINOGENESIS; CELL GROWTH; CHORIOCARCINOMA; CHROMOSOME 7; CHROMOSOME 7P12-7Q11.23; CLINICAL FEATURE; CLONE; CORRELATION FUNCTION; CYTOGENETICS; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG EFFECT; FEMALE; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; GENE SILENCING; GENETIC MARKER; GENETIC POLYMORPHISM; GENOME; GENOME IMPRINTING; HUMAN; HYDATIDIFORM MOLE; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TROPHOBLAST; TROPHOBLASTIC DISEASE; TROPHOBLASTIC TUMOR; TUMOR SUPPRESSOR GENE;

EID: 0347022878     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6934(03)00096-8     Document Type: Review

References (36)

1. Kajii T & Ohama K. Androgenetic origin of hydatidiform mole. Nature 1977; 268: 633-634.
2. Wake N, Takagi N & Sasaki M. Androgenesis as a cause of hydatidiform mole. Journal of the National Cancer Institute 1978; 60: 51-57.
3. Wake N, Shina Y & Ichinoe K. A further cytogenetic study of hydatidiform mole, with reference to its androgenetic origin. Proceedings of the Japan Academy 1978; 54: 533-537.
4. Lawler SD, Pickthall VI, Fisher RA et al. Genetic studies of complete and partial hydatidiform moles. Lancet 1979; 2: 580.
5. Yamashita K, Wake N, Araki T et al. Human lymphocyte antigen expression in hydatidiform mole/: Androgenesis following fertilization by a haploid sperm. American Journal of Obstetrics and Gynecology 1979; 135: 597-600.
6. Jacobs PA, Wilson CM, Sprenkle JA et al. Mechanism of origin of complete hydatidiform moles. Nature 1980; 268: 714-716.
7. Ohama K, Kajji T, Ikamoto E et al. Dispermic origin of XY hydatidiform moles. Nature 1981; 292: 551-552.
8. Wake N, Seki T, Fujita H et al. Malignant potential of homozygous and heterozygous complete moles. Cancer Research 1984; 44: 1226-1230.
9. Wake N, Fujino T, Hoshi S et al. The propensity to malignancy of dispermic heterozygous moles. Placenta 1987; 8: 319-326.
10. Vassilakos P, Riotton G & Kajii T. Hydatidiform mode: Two entities. A morphologic and cytogenetic study with some clinical considerations. American Journal of Obstetrics and Gynecology 1977; 127: 167-170.
11. Szulman AE & Surti U. The syndromes of hydatidiform model. I. Cytogenetic and morphologic correlations. American Journal of Obstetrics and Gynecology 1978; 131: 665-671.
12. Szulman AE, Philippe E, Bou'e JG & Bou'e A. Human triploidy: Association with partial hydatidiform moles and non molar conceptuses. Human Pathology 1981; 12: 1016-1021.
13. Lawler SD, Fisher RA, Pickthall VJ et al. Genetic studies on hydatidiform moles. I. The origin of partial moles. Cancer Genetics and Cytogenetics 1982; 5: 309-320.
14. Sheppard DM, Fisher RA, Lowler SD & Povey S. Tetraploid conceptous with three paternal contributions. Human Genetics 1982; 62: 371-374.
15. Sutri U, Szulman AE, Waquer K et al. Tetraploid partial hydatidiform moles: Two cases with a triple paternal contribution and a 92, XXXY karyotype. Human Genetics 1986; 72: 15-21.
16. Vejerslev LO, Ficher RA, Surti U & Wake N. Hydatidiform mole: Cytogenetically unusual cases and their implications for the present classification. American Journal of Obstetrics and Gynecology 1987; 157: 180-184.
17. Wake N, Tanaka K, Chapman V et al. Chromosomes and cellular origin of choriocarcinoma. Cancer Research 1981; 41: 3137-3143.
18. Fisher RA, Lawler SD, Povey S et al. Genetically homozygous choriocarcinoma following pregnancy with hydatidiform mole. British Journal of Cancer 1988; 58: 788-792.
19. Chaganti RSK, Koduru PRK, Chakraborty R & Jones WB. Genetic origin of a trophoblastic choriocarcinoma. Cancer Research 1990; 50: 6330-6333.
20. Fisher RA, Paradinas FJ, Newland ES & Boxer GM. Genetic evidence that placental site trophoblastic tumours can originate from a hydatidiform mole or a normal conceptus. British Journal of Cancer 1992; 65: 355-358.
21. Fisher RA, Newlands ES, Jeffreys AJ et al. Gestational and nongestational trophoblastic tumours distinguished by DNA analysis. Cancer 1992; 69: 839-845.
22. Arima T, Imamura T, Amada S et al. Genetic origin of malignant trophoblastic neoplasms. Cancer Genetics and Cytogenetics 1994; 73: 95-102.
23. Sasaki S, Katayama PK & Roesler M. Cytogenetic analysis of choriocarcinoma cell lines. Acta Obstetrica et Gynecologica Japonica 1982; 34: 2253-2256.
24. Arima T, Imamura T, Sakuragi N et al. Malignant trophoblastic neoplasms with different modes of origin. Cancer Genetics and Cytogenetics 1995; 85: 5-15.
25. Kato H, Terao Y, Ogawa M et al. Growth-associated gene expression profiles by microarray analysis of trophoblast of molar pregnancies and normal villi. International Journal of Gynecological Pathology 2002; 21: 255-260.
26. Asanoma K, Matsuda T, Konda H et al. NECCI, a candidate choriocarcinoma suppressor gene that encodes homeodomain consensus motif. Genomics 2003; 81: 15-25.
27. Shin CH, Liu ZP, Passier R et al. HOP, an unusual homeodomain protein. Cell 2002; 110: 725-735.
28. Chen F, Kook H, Milewski R et al. Hop is an unusual homeobox gene that modulates cardiac development. Cell 2002; 110: 713-723.
29. Matsuda T, Sasaki M, Kato H et al. Human chromosome carries a putative tumour suppressor gene(s) involved in choriocarcinoma development. Oncogene 1997; 15: 2773-2781.
30. Arima T, Matsuda T, Takagi N et al. Association of IGF1 and H19 imprinting with choriocarcinoma development. Cancer Genetics and Cytogenetics 1997; 93: 39-47.
31. Chilosi M, Piazzola E, Lestani M et al. Differential expression of p57kip2, a maternally imprinted cdk inhibitor, in normal human placenta and gestational trophoblastic disease. Laboratory Investigation 1998; 78: 269-276.
32. Fulop V, Mok SC, Genest DR et al. c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. Journal of Reproductive Medicine 1998; 43: 101-110.
33. Fulop V, Colitti CV, Genest D et al. DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. Oncogene 1998; 17: 419-424.
34. Maruo T & Mochizuki M. Immunohistochemical localization of epidermal growth factor receptor and myc oncogene product in human placenta: Implication for trophoblast proliferation and differentiation. American Journal of Obstetrics and Gynecology 1987; 156: 721-727.
35. Cheung AN, Srivastava G, Pittaluga S et al. Expression of c-myc and c-fms oncogenes in trophoblastic cells in hydatidiform mole and normal human placenta. Journal of Clinical Pathology 1993; 46: 204-207.
36. Sarkar S, Kacinski BM, Kohorn EI et al. Demonstration of myc and ras oncogene expression by hybridization in situ in hydatidiform mole and in the BeWo choriocarcinoma cell line. American Journal of Obstetrics and Gynecology 1986; 154: 390-393.